Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. Show more

Location: Rue Edouard Belin 12, Mont-Saint-Guibert, 1435, Belgium | Website: https://www.nyxoah.com | Industry: Medical Instruments & Supplies | Sector: Healthcare


Market Cap

210.4M

52 Wk Range

$4.34 - $11.87

Previous Close

$4.89

Open

$4.96

Volume

32,273

Day Range

$4.84 - $5.00

Enterprise Value

210.9M

Cash

22.48M

Avg Qtr Burn

-16.98M

Insider Ownership

37.58%

Institutional Own.

17.40%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date